INT284972

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 1.13
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (CDKN2B) nucleus (CDKN2B) kinase activity (CDKN2B)
cytoplasm (CDKN2B)
CDKN2B (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 12 5.00 Very Low Very Low Very Low
Potency 8 5.00 Very Low Very Low Very Low
adenocard 2 5.00 Very Low Very Low Very Low
anticonvulsant 2 5.00 Very Low Very Low Very Low
headache 2 5.00 Very Low Very Low Very Low
gABA 1 5.00 Very Low Very Low Very Low
sodium channel 1 5.00 Very Low Very Low Very Low
interstitial cystitis 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Myelodysplastic Syndromes 116 99.36 Very High Very High Very High
Myeloid Leukemia 92 99.04 Very High Very High Very High
Carcinoma 31 98.80 Very High Very High Very High
Death 8 77.60 Quite High
Apoptosis 27 73.04 Quite High
Fever 10 72.60 Quite High
Chromosome Aberrations 7 60.88 Quite High
Aneuploidy 1 54.88 Quite High
Cancer 122 51.96 Quite High
Encephalopathy 4 39.92 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Both CDKN2A and CDKN2B losses have been well documented in UC, with a CDKN2A deletion often associated with worsened outcomes [24,25].
Negative_regulation (losses) of CDKN2B associated with carcinoma
1) Confidence 0.44 Published 2010 Journal BMC Med Genomics Section Body Doc Link PMC3022544 Disease Relevance 0.27 Pain Relevance 0
In the same way, bisulphite genomic sequencing of the p15 promoter showed 12.2% pre-treatment methylation in 14 of 17 patients treated with Azacitidine. p15 methylation was reduced by 6.8% in 8 of 17 patients, but this did not correlate with response.
Negative_regulation (reduced) of p15
2) Confidence 0.37 Published 2008 Journal Current Medicinal Chemistry Section Body Doc Link PMC2764862 Disease Relevance 0.27 Pain Relevance 0
Gore et al. demonstrated a significant decrease of p15 methylation in MDS and AML patients treated with low-dose azacitidine and the histone deacetylase inhibitor sodium phenylbutyrate.
Negative_regulation (decrease) of p15 associated with myeloid leukemia and myelodysplastic syndromes
3) Confidence 0.37 Published 2008 Journal Current Medicinal Chemistry Section Body Doc Link PMC2764862 Disease Relevance 0.59 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox